Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026

Tango Therapeutics, Inc.

2026-Q1 EPS reported -$0.32 vs consensus -$0.32 ▼ miss (-0.1%)

Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.
Cash $379.8M as of March 31, 2026; runway into 2028.
Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.
Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.
New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026).

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kanishka Pothula

Director, Member of the Nominating and Corporate Governance Committee

TNGX · Tango Therapeutics, Inc.

Effective: 2026-05-13
Filed: May 13, 2026, 4:16 PM ET

Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.

Role change

Sung Lee

Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee

TNGX · Tango Therapeutics, Inc.

Effective: 2026-05-13
Filed: May 13, 2026, 4:16 PM ET

the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.

Departed

Alexis Borisy

Director, Lead Independent Director, Chairperson of the Compensation Committee

TNGX · Tango Therapeutics, Inc.

Effective: 2026-05-13
Filed: May 13, 2026, 4:16 PM ET

On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kanishka Pothula resigned as Director, Member of the Nominating and Corporate Governance Committee at Tango Therapeutics, Inc..

Action: resigned
Role: Director, Member of the Nominating and Corporate Governance Committee

Exact text from the filing

Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sung Lee was appointed as Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee at Tango Therapeutics, Inc..

Action: appointed
Role: Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee

Exact text from the filing

the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexis Borisy resigned as Director, Lead Independent Director, Chairperson of the Compensation Committee at Tango Therapeutics, Inc..

Action: resigned
Role: Director, Lead Independent Director, Chairperson of the Compensation Committee

Exact text from the filing

On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.

View on SEC.gov

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.